AstraZeneca Buys Back 610,000 Shares For Cancellation
24th Jun 2010 08:30
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Thursday it has purchased for cancellation 610,000 of its ordinary shares at a price of 2997 pence per share. MAIN FACTS: -Shares at 0730 GMT up 4.5 pence, or 0.2%, at 3001 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-92
Read moreBMS's Diabetes Drug Dapagliflozin Shows Promise - Lancet
24th Jun 2010 00:01
LONDON (Dow Jones)--Bristol-Myers Squibb Co.'s (BMY) new drug for treating Type-2 diabetes, dapagliflozin, could be considered as a new therapeutic option for patients who have inadequate blood sugar control with first-line drug metformin, and also for early-stage and late-stage diabetes, researcher
Read moreUPDATE:Pfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
23rd Jun 2010 22:56
(Adds details on company's reason for ending the study beginning in fourth paragraph.) By Thomas Gryta and Peter Loftus Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in childre
Read morePfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
23rd Jun 2010 22:40
By Thomas Gryta and Peter Loftus of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controversial area for the drug. The New York-based pharmaceut
Read moreAstraZeneca Buys Back 500,000 Shares At 3041P
23rd Jun 2010 08:06
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Wednesday it has purchased for cancellation 500,000 of its ordinary shares at a price of 3041 pence per share. MAIN FACTS: -Shares at 0705 GMT down 24 pence, or 0.8%, at 3024 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-
Read morePRESS RELEASE: Dapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naive Adults with Type 2 Diabetes
22nd Jun 2010 15:00
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--June 22, 2010-- Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant me
Read morePRESS RELEASE: Dapagliflozin as Monotherapy -2-
22nd Jun 2010 15:00
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors th
Read moreBEFORE THE BELL-2: US HOT STOCKS TO WATCH
21st Jun 2010 13:40
Among the companies expected to actively trade in Monday's session are Anadarko Petroleum Corp. (APC), BP PLC (BP, BP.LN) and American Italian Pasta Co. (AIPC). Anadarko late Friday called the oil spill in the Gulf of Mexico "preventable and the direct result of BP's reckless decisions and acti
Read moreBEFORE THE BELL-2: US HOT STOCKS TO WATCH
21st Jun 2010 10:41
Among the companies expected to actively trade in Monday's session are Anadarko Petroleum Corp. (APC), BP PLC (BP, BP.LN) and CNB Financial Corp. (CCNE). Anadarko late Friday called the oil spill in the Gulf of Mexico "preventable and the direct result of BP's reckless decisions and actions," a
Read moreBEFORE THE BELL: US Stock Futures Rally On China Currency News
21st Jun 2010 10:41
By Steve Goldstein U.S. stock futures, Chinese airlines and natural resource companies led a global advance in equities and commodities markets Monday after China said it would lift the lid on its tightly-controlled currency, spurring expectations for growth in the world's third largest economy
Read moreAstraZeneca Settles Pricing Suit For $103Mln, Denies Wrongdoing
18th Jun 2010 22:17
DOW JONES NEWSWIRES AstraZeneca PLC (AZN) said it would settle a class-action suit over its pricing for wholesale drugs for $103 million even though it believes its pricing and marketing practices were lawful. The suit claimed the company inflated the average wholesale price of expensive dr
Read moreLondon close: Seventh day of gains for Footsie
17th Jun 2010 16:46
London's blue chips rose for the seventh day running as BP took some comfort from the $20bn deal agreed with US president Obama. Banks also rallied on the new plans for City regulation set out yesterday. This afternoon, the coalition government also axed 12 projects costing £2bn, suspended another
Read moreLondon afternoon: Stocks drift off highest levels
17th Jun 2010 14:12
Leading shares saw their gains trimmed over the lunch time session, despite expectations of a firm start on Wall Street. BP and the banks continue to lead the market higher. Under fire oil giant BP remains the top performer after yesterday's meeting between BP officials and the US president. BP h
Read moreLondon midday: Spanish bond sale boosts banks
17th Jun 2010 12:05
BP and the banks are leading the market higher, with the latter in demand after concerns over Spain's ability to raise money on the bond markets were eased by the latest Spanish bond auction, which saw a higher level of demand than the March offering. Royal Bank of Scotland, Lloyds Banking and Bar
Read moreLondon open: BP shares jump
17th Jun 2010 08:29
BP is leading London's blue chips higher in early dealings on Thursday following yesterday's meeting with the US president. BP has cancelled dividends for the rest of the year and agreed to a demand from US president Obama to put $20bn in an escrow account to cover claims resulting from the oil spi
Read more